| Literature DB >> 24956306 |
Keerthana Devarajan1, Hinrich Staecker2, Michael S Detamore3.
Abstract
Sensory neural hearing loss and vestibular dysfunction have become the most common forms of sensory defects, affecting millions of people worldwide. Developing effective therapies to restore hearing loss is challenging, owing to the limited regenerative capacity of the inner ear hair cells. With recent advances in understanding the developmental biology of mammalian and non-mammalian hair cells a variety of strategies have emerged to restore lost hair cells are being developed. Two predominant strategies have developed to restore hair cells: transfer of genes responsible for hair cell genesis and replacement of missing cells via transfer of stem cells. In this review article, we evaluate the use of several genes involved in hair cell regeneration, the advantages and disadvantages of the different viral vectors employed in inner ear gene delivery and the insights gained from the use of embryonic, adult and induced pluripotent stem cells in generating inner ear hair cells. Understanding the role of genes, vectors and stem cells in therapeutic strategies led us to explore potential solutions to overcome the limitations associated with their use in hair cell regeneration.Entities:
Year: 2011 PMID: 24956306 PMCID: PMC4030941 DOI: 10.3390/jfb2030249
Source DB: PubMed Journal: J Funct Biomater ISSN: 2079-4983
Figure 1Classification of inner ear sensory epithelium.
Differences between inner and outer hair cells.
| Arranged in a single row | Arranged in three parallel rows | [ | |
| Round and small | Long and slim | [ | |
| Transduce mechanical energy to neural signals | Appear to impact and regulate the sensitivity of the cochlea over a range of 32 dB | [ | |
| Sensory Neural Hearing loss | Alter properties of cochlear input to the brain | [ | |
| 3,000 to 3,500 | 9,000 to 12,000 | [ |
Figure 2Structure of a typical vestibular hair cell.
Summary of different genes used in inner ear gene therapy.
| Also known as | [ | |
| Mammalian homologues of | [ | |
| Responsible for development of inner ear sensory epithelium and is expressed in supporting cells and inner ear progenitors. Acts upstream of | [ | |
| Member of the notch signaling pathway. Expressed in supporting cells of auditory and vestibular system. Required for the normal development of inner ear sensory organs. | [ | |
| Expressed in neurons and neural precursor cells. Promotes the formation of ganglion neurons in the cochlea. Absence of | [ | |
| Rb1/Rbl2 | Required for hair cell quiescence and cell-cycle exit of embryonic mammalian hair cells but not for their early differentiation. Deletion of Rb1 from progenitor cells leads to aberrant hair cell and supporting cell. Deletion of Rbl2 results in extra row of hair cells and supporting cells in apical regions of the cochlea. | [ |
| Cdkn1b and Cdkn2d | Cyclin-dependent kinase inhibitor. Expressed in sensory progenitors during the early embryonic development of the cochlea. Regulates cell cycle and inhibits hair cell differentiation. | [ |
| MYCN | Member of the | [ |
Figure 3Schematic on the interaction of different genes and their contribution to positive and negative regulation of Math1 transcription factor.
Summary of different viral vectors used in inner ear gene therapy.
|
Transfect a wide variety of cell types in the inner ear including spiral ganglions, outer hair cells, spiral ligament, stria vascularis, and mesenchymal cells in both auditory and vestibular systems. Can produce high titer values that allow injection of small dose volumes for gene therap. Transgene expression up to 3 weeks can be achieved. The short duration of gene expression is ideal for hair cell regeneration because prolonged Effective in delivering Allows insertion of large DNA segments. Recombinant forms can take up to 30kb foreign DNA. Infects dividing and non-dividing cells with very high transduction efficiencies, both Widely researched in clinical studies in both animals and humans, giving a better ability to tackle clinical complications that can arise. |
Evokes a strong host immune response. Does not offer long term gene expression. Entry of the viral vectors is largely dependent on a host receptor called the coxsackie virus receptor (CAR). | [ | |
|
Effectively transfect most inner ear cell types Effective in targeting stria vascularis and delivering tropic factors like NT-3, BDNF, VEGF and FGF. Transgene expression can occur up to 24 weeks Non-toxic to inner ear cells and evokes low immune response.5) Lacks pathogenicity and has never been associated with any known human disease making them suitable for clinical applications. |
Only effective with Successful transgene expression Previous studies haveshown possible dissemination of vector from target tissue. Offers only a limited payload capacity owing to its small size. Risk of insertional mutagenesis. No substantial clinical experience. Vector entry in to host largely depends on heparin sulfate receptor. | [ | |
|
Effectively known to target non-dividing cells, specific to nerve cells, spiral ganglion, vestibular ganglion and mesenchymal cells in mice and guinea pigs. Newer recombinant vectors offer stable and long term gene expression of up to 8 weeks. Can take large DNA fragments. |
Evokes a strong immune response. Transfection is limited only to non-dividing neuronal cells. Large size of the virusmakes it difficult tomanipulate. The virus does not integrate into the host genome; hence gene expression can be unstable. Difficult to produce high titer values and requires injection of high vector volumes. No substantial clinical experience. | [ | |
|
Transfect both dividing and non-dividing cells, including stem cells that are very difficult to transfect. Effectively transduce spiral ganglion neurons and supporting cell Studies indicate transgene expression in perilymphatic space for up to 2 weeks. |
Limited to use in production of genes only in the perilymph. Limited dissemination of vector and not suitable for sensory cell transduction. Failure to transduce cells in the sensory epithelium Can randomly integrate into host chromosome and capable of generating a replication competent virus. No clinical experience and safety concern arise from human immune deficiency virus origin. | [ |